Literature DB >> 23907138

[No improvement in survival with induction chemotherapy prior to chemotherapy in locally advanced head and neck cancer: Results of a randomised phase 3 trial (PARADIGM)].

S Semrau1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23907138     DOI： 10.1007/s00066-013-0420-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

2.  Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.

Authors:  David J Sher; Marshall R Posner; Roy B Tishler; Nicholas J Sarlis; Robert I Haddad; Edward J Holupka; Phillip M Devlin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-06       Impact factor: 7.038

3.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

4.  Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Authors:  Edgar Ben-Josef; Jennifer Moughan; Jaffer A Ajani; Marshall Flam; Leonard Gunderson; JonDavid Pollock; Robert Myerson; Rani Anne; Seth A Rosenthal; Christopher Willett
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

5.  Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.

Authors:  Sabine Semrau; Daniela Schmidt; Michael Lell; Frank Waldfahrer; Sebstian Lettmaier; Torsten Kuwert; Heinrich Iro; Rainer Fietkau
Journal:  Oral Oncol       Date:  2013-01-12       Impact factor: 5.337

6.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

7.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

8.  Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.

Authors:  A Paccagnella; M G Ghi; L Loreggian; A Buffoli; H Koussis; C A Mione; A Bonetti; F Campostrini; G Gardani; A Ardizzoia; D Dondi; M Guaraldi; R Cavallo; L Tomio; A Gava
Journal:  Ann Oncol       Date:  2009-12-23       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.